Annual Report 2005 - Boehringer Ingelheim

Americas
3,670
also contributed positively. spiriva® and the
recently launched product cymbalta® performed
strongly and continued to gain market share.
In Latin America, we implemented a new regional
business concept by implementing a regional
operative unit located in Argentina.
Europe
Our business developed highly satisfactorily in
Europe in 2005. With a growth rate of 15 % and
net sales of EUR 2 billion, we grew about twice as
fast as the market. Our market share increased to
2 %, ranking us as No. 12 in the European pharma-
ceutical market. This success is based on the good
acceptance of our innovative products by physi-
cians and patients.
Europe
2,037
of which:
USA branded
2,592
USA non-branded
535
However, the pharma-political environment in
Europe remained challenging during 2005 and
patient access to new innovative medicines was
often delayed. In addition, cost containment
measures in national healthcare systems mainly
target pharmaceutical spending with mandatory
rebates, repayments and parallel trade.
The main growth driver in 2005 is spiriva®.
Net sales reached EUR 459 million, an increase of
54 % over 2004. spiriva® developed very positively
of which: Germany
455
Asia, Australasia,
Africa
1,312
Sales Prescription Medicines 2005, excluding licenses (in millions of EUR)
in all major markets, reaching market shares of
10–15 % and even up to 20 %.
micardis® / micardisplus® became our second
leading product in Europe, growing with net sales
of EUR 191 million. Newly published data on its
benefits, not only in hypertension but specifically
new benefits for nephroprotection in hypertensive
diabetic patients, is expected to support further
growth.
of which: Japan
801
sifrol®, our leading Parkinson’s medicine, more
than doubled its turnover to EUR 183 million.
Currently it is under registration for RLS. Three
important new introductions to the European
market came in 2005. cymbalta® for MDD. alna
ocas®, a tablet version of our market-leading BPH
product and aptivus®, our HIV treatment.
With the exception of France, all major European
markets gained considerable growth momentum
in 2005. After a difficult year 2004, our German
business developed quite satisfactorily due to the
new introductions of cymbalta®, aptivus® and
alna® ocas® as well as the high market accept-
ance of spiriva®, micardis® and sifrol®.
Dynamic growth was achieved in Central and
Eastern Europe, especially in Russia. Double-digit
growth rates were recorded in Italy, Spain and the
United Kingdom.
The USA remained the
by far most important
market for our drugs.
Prescription Medicines
(which accounted for 76 %
of our net sales) had a
turnover of more than EUR
7.2 billion to which US sales
contributed 43 %.
The Europe Region
achieved 28 % of PM net
sales.
Prescription Medicines